Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
- 30 January 2007
- journal article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 15 (7) , 869-876
- https://doi.org/10.1007/s00520-006-0203-x
Abstract
Patients with prostate cancer metastasized to bone frequently experience skeletal morbidities as a result of their disease. We sought to quantify the longitudinal effects on patient-reported outcomes of skeletal-related events (SREs) and to ascertain the declines in health-related quality of life (HRQOL) and pain experienced by patients who experienced SREs. Data are from a clinical trial for the treatment of SREs associated with advanced prostate cancer metastatic to bone. Outcome measures included the Functional Assessment of Cancer Therapy-General (FACT-G) and the Brief Pain Inventory. Among patients who survived 6 months after randomization, patients with no SREs in the initial 6 months after randomization were matched via propensity scores with those experiencing one or more SREs. Similarly, patients with one SRE were matched with a subset of patients with two or more SREs. Patients with SREs in the initial period had significantly worse survival and HRQOL than those with no SREs. Significant differences were found between the pain differences, FACT-G total scores, and FACT-G physical, emotional, and functional subscales. Comparisons of patients with single vs multiple SREs showed similar patterns. The presence of SREs is significantly associated with worse survival and poorer HRQOL in this patient population. Increasing SRE intensity shows a pattern of increasingly decreased survival and poorer HRQOL.Keywords
This publication has 26 references indexed in Scilit:
- Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important DifferencesEvaluation & the Health Professions, 2005
- The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancerAnnals of Oncology, 2005
- Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone LesionsMedical Care, 2004
- Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical EndpointsAmerican Journal of Clinical Oncology, 2002
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePAIN®, 2001
- INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINEJournal of Urology, 2000
- Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrumentUrology, 1997
- Estimating Causal Effects from Large Data Sets Using Propensity ScoresAnnals of Internal Medicine, 1997
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Some large‐sample distribution‐free estimators and tests for multivariate partially incomplete data from two populationsStatistics in Medicine, 1992